US 12,215,099 B2
Quinolinone and benzoxazine derivatives as muscarinic M1 and/or M4 receptor agonists
Giles Albert Brown, Cambridge (GB); Miles Stuart Congreve, Cambridge (GB); Benjamin Gerald Tehan, Cambridge (GB); and Mark Pickworth, Cambridge (GB)
Assigned to Nxera Pharma UK Limited, Cambridge (GB)
Appl. No. 17/311,212
Filed by Nxera Pharma UK Limited, Cambridge (GB)
PCT Filed Dec. 9, 2019, PCT No. PCT/GB2019/053467
§ 371(c)(1), (2) Date Jun. 4, 2021,
PCT Pub. No. WO2020/115506, PCT Pub. Date Jun. 11, 2020.
Claims priority of application No. 1819961 (GB), filed on Dec. 7, 2018.
Prior Publication US 2022/0017504 A1, Jan. 20, 2022
Int. Cl. C07D 413/14 (2006.01); C07D 471/08 (2006.01)
CPC C07D 413/14 (2013.01) [C07D 471/08 (2013.01)] 11 Claims
 
1. A compound of the formula (I):

OG Complex Work Unit Chemistry
or a salt thereof, wherein:
R1 is:

OG Complex Work Unit Chemistry
n is 1, 2, 3 or 4;
X1 is CH2 or O;
Y is N or CH;
X2 and X3 are saturated hydrocarbon groups which together contain a total of four to six carbon atoms and which link together such that the moiety:

OG Complex Work Unit Chemistry
represents a monocyclic or bicyclic ring system;
Z is CH2 or CO;
X4 is CH2 or O;
and R2 is F or H.